Targeted drugs, such as FGFR2 inhibitors and IDH1 inhibitors, block tumour cell proliferation and signalling pathways, thus increasing the effectiveness of immunotherapy and restoring the ability of the immune system to recognize tumours (116, 117). The gene discussed is FGFR2; the disease is neoplasm.